Free Trial
OTCMKTS:OPHLF

Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis

Ono Pharmaceutical logo
$10.38 0.00 (0.00%)
As of 05/28/2025

About Ono Pharmaceutical Stock (OTCMKTS:OPHLF)

Key Stats

Today's Range
$10.38
$10.38
50-Day Range
$9.40
$12.75
52-Week Range
$9.20
$16.05
Volume
N/A
Average Volume
8,600 shs
Market Capitalization
$4.87 billion
P/E Ratio
9.98
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

OPHLF Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
Nectar Classic Hybrid Mattress review 2024
See More Headlines

OPHLF Stock Analysis - Frequently Asked Questions

Ono Pharmaceutical's stock was trading at $9.60 at the beginning of the year. Since then, OPHLF stock has increased by 8.1% and is now trading at $10.3780.
View the best growth stocks for 2025 here
.

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) posted its quarterly earnings data on Monday, February, 3rd. The company reported $0.21 EPS for the quarter. Ono Pharmaceutical had a net margin of 15.15% and a trailing twelve-month return on equity of 9.10%.

Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
2/03/2025
Today
5/29/2025
Next Earnings (Estimated)
7/28/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:OPHLF
Employees
3,853
Year Founded
N/A

Profitability

Trailing P/E Ratio
9.98
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$883.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.48 billion
Cash Flow
$1.97 per share
Price / Cash Flow
5.28
Book Value
$11.54 per share
Price / Book
0.90

Miscellaneous

Free Float
N/A
Market Cap
$4.87 billion
Optionable
Not Optionable
Beta
0.60
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:OPHLF) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners